We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
In the latest close session, AbbVie (ABBV - Free Report) was up +1.78% at $261.70. This change outpaced the S&P 500's 0.48% loss on the day. At the same time, the Dow lost 0.29%, and the tech-heavy Nasdaq lost 0.56%.
The drugmaker's stock has climbed by 3.07% in the past month, exceeding the Medical sector's loss of 2.01% and the S&P 500's loss of 0.82%.
The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming release. In that report, analysts expect AbbVie to post earnings of $3.86 per share. This would mark year-over-year growth of 107.53%. Simultaneously, our latest consensus estimate expects the revenue to be $17.36 billion, showing a 10.02% escalation compared to the year-ago quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $14.05 per share and revenue of $67.56 billion. These results would represent year-over-year changes of +40.5% and +10.47%, respectively.
It is also important to note the recent changes to analyst estimates for AbbVie. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.09% lower. AbbVie is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, AbbVie is currently trading at a Forward P/E ratio of 18.3. This indicates a premium in contrast to its industry's Forward P/E of 15.51.
We can additionally observe that ABBV currently boasts a PEG ratio of 1.16. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.98 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 104, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
In the latest close session, AbbVie (ABBV - Free Report) was up +1.78% at $261.70. This change outpaced the S&P 500's 0.48% loss on the day. At the same time, the Dow lost 0.29%, and the tech-heavy Nasdaq lost 0.56%.
The drugmaker's stock has climbed by 3.07% in the past month, exceeding the Medical sector's loss of 2.01% and the S&P 500's loss of 0.82%.
The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming release. In that report, analysts expect AbbVie to post earnings of $3.86 per share. This would mark year-over-year growth of 107.53%. Simultaneously, our latest consensus estimate expects the revenue to be $17.36 billion, showing a 10.02% escalation compared to the year-ago quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $14.05 per share and revenue of $67.56 billion. These results would represent year-over-year changes of +40.5% and +10.47%, respectively.
It is also important to note the recent changes to analyst estimates for AbbVie. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.09% lower. AbbVie is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, AbbVie is currently trading at a Forward P/E ratio of 18.3. This indicates a premium in contrast to its industry's Forward P/E of 15.51.
We can additionally observe that ABBV currently boasts a PEG ratio of 1.16. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.98 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 104, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.